Pharminent

Merck licenses Teijin Pharma’s Alzheimer’s candidate

Merck has signed a worldwide license agreement with Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical antibody candidate targeting the protein tau. http://drugdiscovery.pharmaceutical-business-review.com/news/merck-tejin-sign-license-agreement-for-tau-targeting-antibody-260517-5825579

Filed under: Alzheimer’s